Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Josh Lipton takes a closer look at the top stories investors need to know after the closing bell on Asking for a Trend. Hims ...
Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...
Reports Q4 revenue $481.1M, consensus $470.5M. “2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages ...
Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
3don MSN
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback